Bicalutamide (‘Casodex’) 150mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: Results from the randomised Early Prostate Cancer Programme

Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review

“…The duration of ADT use in this setting should be 2-3 years. Since the publication of the ASCO guideline, a subgroup analysis of the Early Prostate Cancer program in men undergoing radiotherapy has also been published, demonstrating a survival advantage with adjuvant bicalutamide [27]. Whether bicalutamide has equivalent efficacy to medical or surgical castration is still unclear.…”

Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes

“…However, that study implies a considerable risk of underreporting because Radiotherapy and antiandrogens for prostate cancer A Berg et al adverse events were reported 'spontaneously' by the patients. 27 Further, the median duration of bicatulamide treatment was only 1.8 years. Our findings may be somewhat provocative to the opinion that sexual function is maintained during AA treatment and is at least better than during medical castration.…”

Association hormonothérapie et radiothérapie dans le cancer de prostate localement avancé

“…Une seule très large étude a associé à l'irradiation le bicalutamide à la dose de 150 mg par jour pendant cinq ans. Cette étude a montré un bénéfice en survie au traitement combiné comparé à l'irradiation exclusive [27]. Cependant, cette étude souffre de biais méthodologiques majeurs et ne permet pas de proposer en standard cette association.…”